Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
Celgene
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Mirna Therapeutics, Inc.
National Cancer Institute (NCI)
Case Comprehensive Cancer Center